Article
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial.
Gastroenterology - 1 Nov 2013
Poordad Fred, Lawitz Eric, Reddy K Rajender, Afdhal Nezam H, Hézode Christophe, Zeuzem Stefan, Lee Samuel S, Calleja Jose Luis, Brown Robert S, Craxi Antonio, Wedemeyer Heiner, Nyberg Lisa, Nelson David R, Rossaro Lorenzo, Balart Luis, Morgan Timothy R, Bacon Bruce R, Flamm Steven L, Kowdley Kris V, Deng Weiping, Koury Kenneth J, Pedicone Lisa D, Dutko Frank J, Burroughs Margaret H, Alves Katia, Wahl Janice, Brass Clifford A, Albrecht Janice K, Sulkowski Mark S
Abstract excerpt
BACKGROUND & AIMS: Treatment of hepatitis C virus (HCV) infection with boceprevir, peginterferon, and ribavirin can lead to anemia, which has been managed by reducing ribavirin dose and/or erythropoietin therapy. We assessed the effects of these anemia management strategies on rates of sustained virologic response (SVR) and safety. METHODS: Patients (n = 687) received 4 weeks of peginterferon and ribavirin...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.